Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that ...

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - announced the initiation of dosing in the global clinical ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

Biogen's BIIB short percent of float has risen 3.1% since its last report. The company recently reported that it has 3.88 ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...